Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Condylomata Acuminata 3Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Keratosis, Actinic 2Head and Neck Neoplasms 2Breast Neoplasms 2Wounds and Injuries 1Virus Diseases 1Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Squamous Intraepithelial Lesions 1Skin Neoplasms 1Sexually Transmitted Diseases 1Parapsoriasis 1Papillomavirus Infections 1Non-Muscle Invasive Bladder Neoplasms 1Non-Melanoma Skin Cancers 1Lymphoma, Follicular 1Keratosis, Seborrheic 1Hypogonadism 1Hemangioma, Cavernous 1Hemangioma 1Fatigue 1Exanthema 1Eunuchism 1Dermatitis, Contact 1

Interventions

ledipasvir, sofosbuvir drug combination 1VP-102 1Therapies, Investigational 1Rituximab 1Kidney Transplantation 1Imiquimod 1Gels 1Cantharidin 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Virus Diseases × Gels × Clear all
NCT02724254 2018-07-20

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Vaxart

Phase 2 Completed
218 enrolled

Condylomata Acuminata, Sexually Transmitted Diseases, Virus Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡